GlassScriptPhysician profile
Chase R Herdman
NPI 1457446064
$6,451.70
in general payments reported to CMS, 2019-2025
38 companies · $998 in 2025
The $998 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $381 · 2021: $632 · 2022: $1,214 · 2023: $1,382 · 2024: $1,135 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,682.72 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $612.70 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $497.75 | 2019-2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $448.40 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $405.26 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $369.60 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $323.65 | 2019-2024 | |
| Genzyme Corporation | $202.91 | 2023-2025 | |
| Ethicon US, LLC | $182.93 | 2019-2022 | |
| Boston Scientific Corporation | $163.44 | 2020-2023 | Cre Pro, Compliance Endokit |
| Braintree Laboratories, INC. | $161.36 | 2019-2025 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $159.40 | 2019-2025 | Stelara, Tremfya, Remicade |
| Lilly USA, LLC | $117.64 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $110.09 | 2021-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $102.77 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $95.59 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $86.29 | 2021-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $78.22 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $77.94 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $55.38 | 2022-2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $54.73 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $51.06 | 2021-2023 | |
| Enterra Medical, INC. | $50.50 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $46.94 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $43.24 | 2022-2023 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $36.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.80 | 2023-2024 | Cyltezo |
| Shionogi INC | $31.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.34 | 2022 | |
| Amgen INC. | $22.76 | 2022 | |
| Madrigal Pharmaceuticals | $22.74 | 2025 | Rezdiffra |
| Organon LLC | $21.34 | 2022-2023 | Hadlima |
| Evoke Pharma, INC. | $19.30 | 2024 | |
| Fresenius Kabi USA, LLC | $17.11 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $15.45 | 2024 | |
| Medtronic, INC. | $12.70 | 2022 | |
| Allergan, INC. | $11.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Herdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.